Old Web
English
Sign In
Acemap
>
authorDetail
>
John G. Mears
John G. Mears
Columbia University Medical Center
Medicine
Rigosertib
Myelodysplastic syndromes
Lower risk
Immunology
3
Papers
23
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Final Analysis of the Phase 1a/b Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients with Relapsed or Refractory AL Amyloidosis
2017
Blood
Camille V. Edwards
Julia Gould
Arielle L. Langer
Markus Y. Mapara
Jai Radhakrishnan
Mathew S. Maurer
Shahzad Raza
John G. Mears
Siyang Leng
Jonathan S. Wall
Andrew Eisenberger
Alan Solomon
Suzanne Lentzsch
Show All
Source
Cite
Save
Citations (14)
Rigosertib Oral in Transfusion Dependent Lower Risk Myelodysplastic Syndromes (LR-MDS): Optimization of Dose and Rate of Transfusion Independence (TI) or Transfusion Reduction (TR) in a Single-Arm Phase 2 Study
2017
Blood
Azra Raza
Aref Al-Kali
Raoul Tibes
Gary Spitzer
Manila Gaddh
Benjamin Tycko
Sangmin Lee
Naomi Galili
Abdullah Mahmood Ali
John G. Mears
Siddhartha Mukherjee
Ryan Shelton
Steven Fruchtman
Michael E. Petrone
Patrick S Zbyszewski
Mark L. Heaney
Show All
Source
Cite
Save
Citations (3)
Oral Rigosertib (ON 01910.Na) Treatment Produces An Encouraging Rate Of Transfusion Independence In Lower Risk Myelodysplastic Syndromes (MDS) Patients; A Genomic Methylation Profile Is Associated With Responses
2013
Blood
Azra Raza
Benjamin Tycko
Sangmin Lee
Naomi Galili
Abdullah Mahmood Ali
Andrew Eisenberger
John G. Mears
Aref Al-Kali
Raoul Tibes
Gary Spitzer
Francois Wilhelm
Siddhartha Mukherjee
Show All
Source
Cite
Save
Citations (6)
1